Inactivation of Streptococcus pyogenes extracellular cysteine protease significantly decreases mouse lethality of serotype M3 and M49 strains.

Cysteine proteases have been implicated as important virulence factors in a wide range of prokaryotic and eukaryotic pathogens, but little direct evidence has been presented to support this notion. Virtually all strains of the human bacterial pathogen Streptococcus pyogenes express a highly conserved extracellular cysteine protease known as streptococcal pyrogenic exotoxin B (SpeB). Two sets of isogenic strains deficient in SpeB cysteine protease activity were constructed by integrational mutagenesis using nonreplicating recombinant plasmids containing a truncated segment of the speB gene. Immunoblot analyses and enzyme assays confirmed that the mutant derivatives were deficient in expression of enzymatically active SpeB cysteine protease. To test the hypothesis that the cysteine protease participates in host mortality, we assessed the ability of serotype M3 and M49 wild-type strains and isogenic protease-negative mutants to cause death in outbred mice after intraperitoneal inoculation. Compared to wild-type parental organisms, the serotype M3 speB mutant lost virtually all ability to cause mouse death (P < 0.00001), and similarly, the virulence of the M49 mutant was detrimentally altered (P < 0.005). The data unambiguously demonstrate that the streptococcal enzyme is a virulence factor, and thereby provide additional evidence that microbial cysteine proteases are critical in host-pathogen interactions.

[1]  J. Musser Streptococcal superantigen, mitogenic factor, and pyrogenic exotoxin B expressed by Streptococcus pyogenes. Structure and function. , 1997, Preparative biochemistry & biotechnology.

[2]  R. Kaul,et al.  Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G , 1996, Infection and immunity.

[3]  A. Podbielski,et al.  What is the size of the group A streptococcal vir regulon? The Mga regulator affects expression of secreted and surface virulence factors , 1996, Medical Microbiology and Immunology.

[4]  J. Musser,et al.  Horizontal gene transfer among group A streptococci: implications for pathogenesis and epidemiology. , 1996, Trends in microbiology.

[5]  A. M. Marciel,et al.  Activation of a 66-kilodalton human endothelial cell matrix metalloprotease by Streptococcus pyogenes extracellular cysteine protease , 1996, Infection and immunity.

[6]  H. Kuramitsu,et al.  Role of Porphyromonas gingivalis protease activity in colonization of oral surfaces , 1996, Infection and immunity.

[7]  A. Podbielski,et al.  Molecular characterization of group A streptococcal (GAS) oligopeptide permease (Opp) and its effect on cysteine protease production , 1996, Molecular microbiology.

[8]  L. Björck,et al.  Streptococcal cysteine proteinase releases kinins: a virulence mechanism , 1996, The Journal of experimental medicine.

[9]  J. Musser,et al.  Substitution of cysteine 192 in a highly conserved Streptococcus pyogenes extracellular cysteine protease (interleukin 1beta convertase) alters proteolytic activity and ablates zymogen processing , 1996, Infection and immunity.

[10]  J. Musser,et al.  Streptococcal cysteine protease augments lung injury induced by products of group A streptococci , 1996, Infection and immunity.

[11]  T. File,et al.  Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  P. Carmeliet,et al.  Generation and characterization of urokinase receptor-deficient mice. , 1996, The Journal of clinical investigation.

[13]  J. Potempa,et al.  Porphyromonas gingivalis: a proteinase/gene accounting audit. , 1995, Trends in microbiology.

[14]  J. Musser,et al.  Different forms of streptolysin O produced by Streptococcus pyogenes and by Escherichia coli expressing recombinant toxin: cleavage by streptococcal cysteine protease , 1995, Infection and immunity.

[15]  A. Shaw,et al.  Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. , 1995, Immunity.

[16]  L. Björck,et al.  Streptococcal Cysteine Proteinase Releases Biologically Active Fragments of Streptococcal Surface Proteins (*) , 1995, The Journal of Biological Chemistry.

[17]  H. Fletcher,et al.  Virulence of a Porphyromonas gingivalis W83 mutant defective in the prtH gene , 1995, Infection and immunity.

[18]  J. Musser,et al.  Genetic diversity and relationships among Streptococcus pyogenes strains expressing serotype M1 protein: recent intercontinental spread of a subclone causing episodes of invasive disease , 1995, Infection and immunity.

[19]  R. Kamen,et al.  Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock , 1995, Cell.

[20]  J. Musser,et al.  Proteolytically active streptococcal pyrogenic exotoxin B cleaves monocytic cell urokinase receptor and releases an active fragment of the receptor from the cell surface. , 1994, The Journal of biological chemistry.

[21]  J. Musser,et al.  Non‐congruent relationships between variation in emm gene sequences and the population genetic structure of group A streptococci , 1994, Molecular microbiology.

[22]  J. Musser,et al.  Vaccination with streptococcal extracellular cysteine protease (interleukin-1 beta convertase) protects mice against challenge with heterologous group A streptococci. , 1994, Microbial pathogenesis.

[23]  K. Gase,et al.  Inactivation of the streptokinase gene prevents Streptococcus equisimilis H46A from acquiring cell-associated plasmin activity in the presence of plasminogen. , 1994, FEMS microbiology letters.

[24]  J. Musser,et al.  A conserved Streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin. , 1993, Microbial pathogenesis.

[25]  M. Chaussee,et al.  Inactivation of the streptococcal erythrogenic toxin B gene (speB) in Streptococcus pyogenes , 1993, Infection and immunity.

[26]  J. Musser,et al.  Cleavage of interleukin 1 beta (IL-1 beta) precursor to produce active IL-1 beta by a conserved extracellular cysteine protease from Streptococcus pyogenes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Schwartz,et al.  Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome , 1993, Infection and immunity.

[28]  D. Musher,et al.  Geographic and temporal distribution and molecular characterization of two highly pathogenic clones of Streptococcus pyogenes expressing allelic variants of pyrogenic exotoxin A (Scarlet fever toxin). , 1993, The Journal of infectious diseases.

[29]  J. Joseph,et al.  Novel streptococcal-integration shuttle vectors for gene cloning and inactivation. , 1992 .

[30]  Dwight R. Johnson,et al.  Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. , 1992, The Journal of infectious diseases.

[31]  B. Schwartz,et al.  Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  S. Holm,et al.  Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. , 1992, The Journal of infectious diseases.

[33]  J. Musser,et al.  Characterization and clonal distribution of four alleles of the speA gene encoding pyrogenic exotoxin A (scarlet fever toxin) in Streptococcus pyogenes , 1991, The Journal of experimental medicine.

[34]  J. Goldberg,et al.  Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Musser,et al.  Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Ferretti,et al.  Frequency of the erythrogenic toxin B and C genes (speB and speC) among clinical isolates of group A streptococci , 1991, Infection and immunity.

[37]  P. Schlievert,et al.  Nucleotide sequence of the streptococcal pyrogenic exotoxin type B gene and relationship between the toxin and the streptococcal proteinase precursor , 1990, Journal of bacteriology.

[38]  I. Olafsson,et al.  Bacterial growth blocked by a synthetic peptide based on the structure of a human proteinase inhibitor , 1989, Nature.

[39]  S. Twining Fluorescein isothiocyanate-labeled casein assay for proteolytic enzymes. , 1984, Analytical biochemistry.

[40]  H. Knöll,et al.  Isolation and characterization of erythrogenic toxins. V. Communication: identity of erythrogenic toxin type B and streptococcal proteinase precursor. , 1983, Zentralblatt fur Bakteriologie, Mikrobiologie und Hygiene. 1. Abt. Originale A, Medizinische Mikrobiologie, Infektionskrankheiten und Parasitologie = International journal of microbiology and hygiene. A, Medical microbiology, infectious....

[41]  R. Kessler,et al.  Growth characteristics of group A streptococci in a new chemically defined medium , 1980, Infection and immunity.

[42]  C. A. Ogburn,et al.  The determination of streptococcal antiproteinase titers in sera of patients with rheumatic fever and streptococcal infection. , 1958, Journal of immunology.

[43]  C. A. Ogburn,et al.  EXTRACELLULAR ANTIGENS IN STEADY-STATE CULTURES OF THE HEMOLYTIC STREPTOCOCCUS: PRODUCTION OF PROTEINASE AT LOW pH , 1958, Journal of Bacteriology.

[44]  A. Kellner,et al.  MYOCARDIAL NECROSIS PRODUCED IN ANIMALS BY MEANS OF CRYSTALLINE STREPTOCOCCAL PROTEINASE , 1954, The Journal of experimental medicine.

[45]  E. W. Todd A STUDY OF THE INHIBITION OF STREPTOCOCCAL PROTEINASE BY SERA OF NORMAL AND IMMUNE ANIMALS AND OF PATIENTS INFECTED WITH GROUP A HEMOLYTIC STREPTOCOCCI , 1947, The Journal of experimental medicine.

[46]  S. Elliott A PROTEOLYTIC ENZYME PRODUCED BY GROUP A STREPTOCOCCI WITH SPECIAL REFERENCE TO ITS EFFECT ON THE TYPE-SPECIFIC M ANTIGEN , 1945, The Journal of experimental medicine.

[47]  E. Hendry,et al.  THE IMMUNISING ACTIVITY OF CERTAIN CHEMICAL FRACTIONS ISOLATED FROM HÆMOLYTIC STREPTOCOCCI , 1937 .

[48]  J. Musser,et al.  6 The revival of group A streptococcal diseases, with a commentary on staphylococcal toxic shock syndrome , 1998 .

[49]  J. Musser,et al.  An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. , 1997, JAMA.

[50]  P. Rosenthal,et al.  The proteases and pathogenicity of parasitic protozoa. , 1993, Annual review of microbiology.

[51]  J. Ferretti,et al.  Novel streptococcal-integration shuttle vectors for gene cloning and inactivation. , 1992, Gene.